Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc G Ghany

Showing results (141-150 of 182) with videos related to

Pageof 19
Sort By:
Gastroenterology|September 15, 2009
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trialMitchell L Shiffman, Chihiro Morishima, Jules L Dienstag, et al.
Gastroenterology|January 24, 2007
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis CMitchell L Shiffman, Marc G Ghany, Timothy R Morgan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2021
Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus CoinfectionMandana Khalili, Wendy C King, David E Kleiner, et al.
Hepatology (Baltimore, Md.)|April 12, 2011
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferonAdrian M Di Bisceglie, Anne M Stoddard, Jules L Dienstag, et al.
Hepatology (Baltimore, Md.)|April 19, 2023
Use of HBV RNA and to predict change in serological status and disease activity in CHBMarc G Ghany, Wendy C King, Amanda S Hinerman, et al.
Controlled Clinical Trials|October 7, 2004
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonrespondersWilliam M Lee, Jules L Dienstag, Karen L Lindsay, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trialGregory T Everson, John C Hoefs, Leonard B Seeff, et al.
The American Journal of Gastroenterology|October 29, 2019
Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level ViremiaKali Zhou, Abdus S Wahed, Stewart Cooper, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 1, 2022
A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus CoinfectionRaymond T Chung, Wendy C King, Marc G Ghany, et al.
Hepatology (Baltimore, Md.)|October 14, 2009
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trialZachary D Goodman, Anne M Stoddard, Herbert L Bonkovsky, et al.
Pageof 19

Showing results (141-150 of 182) with videos related to

Sort By:
Pageof 19
Gastroenterology|September 15, 2009
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trialMitchell L Shiffman, Chihiro Morishima, Jules L Dienstag, et al.
Gastroenterology|January 24, 2007
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis CMitchell L Shiffman, Marc G Ghany, Timothy R Morgan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2021
Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus CoinfectionMandana Khalili, Wendy C King, David E Kleiner, et al.
Hepatology (Baltimore, Md.)|April 12, 2011
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferonAdrian M Di Bisceglie, Anne M Stoddard, Jules L Dienstag, et al.
Hepatology (Baltimore, Md.)|April 19, 2023
Use of HBV RNA and to predict change in serological status and disease activity in CHBMarc G Ghany, Wendy C King, Amanda S Hinerman, et al.
Controlled Clinical Trials|October 7, 2004
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonrespondersWilliam M Lee, Jules L Dienstag, Karen L Lindsay, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trialGregory T Everson, John C Hoefs, Leonard B Seeff, et al.
The American Journal of Gastroenterology|October 29, 2019
Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level ViremiaKali Zhou, Abdus S Wahed, Stewart Cooper, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 1, 2022
A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus CoinfectionRaymond T Chung, Wendy C King, Marc G Ghany, et al.
Hepatology (Baltimore, Md.)|October 14, 2009
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trialZachary D Goodman, Anne M Stoddard, Herbert L Bonkovsky, et al.
Pageof 19